Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Accounts Payables (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Accounts Payables data on record, last reported at $783103.0 in Q3 2025.

  • For Q3 2025, Accounts Payables fell 30.96% year-over-year to $783103.0; the TTM value through Sep 2025 reached $783103.0, down 30.96%, while the annual FY2024 figure was $1.3 million, 10.56% down from the prior year.
  • Accounts Payables reached $783103.0 in Q3 2025 per COEP's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.4 million in Q4 2023 and bottomed at $31816.0 in Q1 2021.
  • Average Accounts Payables over 5 years is $714842.1, with a median of $783103.0 recorded in 2025.
  • Peak YoY movement for Accounts Payables: skyrocketed 2913.37% in 2022, then crashed 65.58% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $134092.0 in 2021, then dropped by 26.15% to $99021.0 in 2022, then soared by 1333.74% to $1.4 million in 2023, then fell by 10.56% to $1.3 million in 2024, then tumbled by 38.33% to $783103.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $783103.0 in Q3 2025, $1.0 million in Q2 2025, and $1.1 million in Q1 2025.